Ning Meng

The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2

Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach

Plasticenta: First evidence of microplastics in human placenta

The enigma of ceramide synthase regulation in mammalian cells

Sphingolipids and their metabolism in physiology and disease

Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders

Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development

Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer's disease

PROTAC targeted protein degraders: the past is prologue

Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

<p>Reactive Oxygen Species: Drivers of Physiological and Pathological Processes</p>

Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions

Nrf2 activation improves experimental rheumatoid arthritis

Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the Placenta

KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

Magnetite pollution nanoparticles in the human brain

Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1–Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases

Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)

VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microRNA secretion and smooth muscle hyperplasia

Fragment-growing guided design of Keap1-Nrf2 protein-protein interaction inhibitors for targeting myocarditis

Nano-Mg(OH)2-induced proliferation inhibition and dysfunction of human umbilical vein vascular endothelial cells through caveolin-1-mediated endocytosis

An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice

A novel curcumin-loaded nanoparticle restricts atherosclerosis development and promotes plaques stability in apolipoprotein E deficient mice

Identification of a novel small-molecule Keap1–Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy

A new microRNA signal pathway regulated by long noncoding RNA TGFB2-OT1 in autophagy and inflammation of vascular endothelial cells

Methoxy poly (ethylene glycol)-b-poly (δ-valerolactone) copolymeric micelles for improved skin delivery of ketoconazole